Eparel 50 Tablets (Epalrestat 50 mg).

• Composition :
  Each film coated tablet contains Epalrestat 50 mg.
• Indications :
  Indicated for the treatment of diabetic neuropathy.
• Pharmacodynamics :
  Epalrestat is an aldose reductase inhibitor. Aldose reductase reduses glucose to sorbitol. Epalrestat inhibited high glucose-mediated neutrophil endothelial cell adhesion and expression of endothelial adhesion molecules not only through inhibition of a PKC-dependent pathway, but also through increased endothelial NO production.
• Dosage and administration :
  1 tablet thrice daily before meals
• Contraindications :
  Contraindicated in patients with known hypersensitivity to any other component of this product.
• Precautions and warnings :
  The efficacy of this product has not been established in patients with diabetic peripheral neuropathy with irreversible organic changes. The patient should be carefully monitored during the administration of this product. When the efficacy of this product is not observed even after 12 weeks of administration, other appropriate therapies should be taken.
• Use in pregnancy, lactation & pediatrics :
  There are no adequate and well-controlled studies in human pregnancy, lactation & children. This product should only be used in pregnancy if considered essential by the physician.
• Drug interactions :
  No drug- drug interaction reported.
• Adverse reactions :
  Major adverse reactions are hepatic function abnormalities thrombocytopenia. malaise, headache, abdominal pain, nausea, hypersensitivity reaction etc.
• Therapy Area :
  Nutraceuticals and Immunoceuticals